Is There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?

Simple item page
dc.contributor.authorBilaç Ö.
dc.contributor.authorTahlllloǧlu A.
dc.contributor.authorÇaklr B.
dc.contributor.authorKavurma C.
dc.contributor.authorÖnder A.
dc.contributor.authorErcan E.S.
dc.date.accessioned2024-07-22T08:02:05Z
dc.date.available2024-07-22T08:02:05Z
dc.date.issued2023
dc.description.abstractObjective: We aimed to investigate the risk of antipsychotic drug treatment in the development of metabolic syndrome (MetS) in children and adolescents and to determine which psychiatric disorder is more associated with MetS in the pediatric population. Methods: The sample consisted of 118 children and adolescents (88 used psychotropic medication). The hemogram, fasting blood glucose, lipid profile, weight, and blood pressure levels of all the participants and information regarding medication doses of the patient group at the sixth month of the treatment process were obtained. Results: Bipolar disorder (BPD) was the only psychiatric disorder associated with MetS. Quetiapine and valproic acid were found to have increasing effects on MetS. Weight gain and the increase in systolic and diastolic blood pressure significantly increased the likelihood of MetS. Hierarchical logistic regression analyses revealed that quetiapine increased the risk of MetS through weight gain, and valproic acid increased MetS risk through systolic blood pressure. Conclusion: Especially BPD and psychotropic use in children and adolescents disrupt metabolic regulation and pose a risk for MetS. Determining the risk factors causing MetS, especially in children and adolescents, plays a significant role in preventing mortality and morbidity at advanced ages. © 2023 S. Karger AG. All rights reserved.
dc.identifier.DOI-ID10.1159/000533470
dc.identifier.issn2571726X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11711
dc.language.isoEnglish
dc.publisherS. Karger AG
dc.rightsAll Open Access; Gold Open Access
dc.subjectantidepressant agent
dc.subjectaripiprazole
dc.subjectmethylphenidate
dc.subjectmood stabilizer
dc.subjectolanzapine
dc.subjectpsychostimulant agent
dc.subjectpsychotropic agent
dc.subjectquetiapine
dc.subjectvalproic acid
dc.subjectadolescent
dc.subjectArticle
dc.subjectbipolar disorder
dc.subjectblood pressure
dc.subjectchild
dc.subjectchild psychiatry
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectfemale
dc.subjectglucose blood level
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectKolmogorov Smirnov test
dc.subjectmajor clinical study
dc.subjectmajor depression
dc.subjectmale
dc.subjectmaternal smoking
dc.subjectmental disease
dc.subjectmetabolic parameters
dc.subjectmetabolic regulation
dc.subjectmetabolic syndrome X
dc.subjectpsychosis
dc.subjectSchedule for Affective Disorders and Schizophrenia
dc.subjectsocial status
dc.subjectsociology
dc.titleIs There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu